Deka Biosciences

Deka Biosciences is an early-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn's disease, psoriasis, rheumatoid arthritis, and sepsis. The company is led by serial entrepreneur John Mumm and supported by a team of experienced biopharmaceutical and CDMO innovators with expertise in drug discovery, product development, characterization, and testing. Deka Biosciences has developed Diakines™ for targeted disease treatment, improving pharmacokinetic/pharmacodynamic (PK/PD) functions by delivering dual and complementary cytokines directly to affected tissues or cells, thereby maximizing patient benefits. Through the use of precision medicine, Deka Biosciences envisions maximizing the impact of its Diakine™ therapeutic proteins by treating patients who benefit from and respond to their cytokine therapies.